Drug intelligence / Profile preview

ICE 1204

Development stage: Preclinical
Lead developer: iCeutica
Modality: Small Molecules
Administration: Inhalation

Overview

ICE 1204 is a preclinical-stage small molecule therapeutic being developed by iCeutica for the treatment of respiratory and allergic diseases, including asthma and chronic obstructive pulmonary disease (COPD). The drug is designed for inhaled administration. iCeutica utilizes its proprietary SoluMatrix Fine Particle Technology to produce sub-micron drug particles, which aims to improve the solubility and bioavailability of the active pharmaceutical ingredient. As of the latest pipeline updates, the specific biological target and the identity of the small molecule have not been publicly disclosed.

Targets

AChR (Acetylcholine receptor)

Beyond the preview

Go deeper on ICE 1204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICE 1204.

Explore the full profile